Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
諾和諾德宣佈SOUL心血管結果試驗實現其首要目標，通過展示接受口服塞麥欣治療的人群，在MACE方面實現了14%的統計上顯著且更優越的減少，與安慰劑相比
Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
諾和諾德宣佈SOUL心血管結果試驗實現其首要目標，通過展示接受口服塞麥欣治療的人群，在MACE方面實現了14%的統計上顯著且更優越的減少，與安慰劑相比
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間